Certain infectious and parasitic diseases
Conditions
Interventions
The present study proposes to evaluate the immunogenicity of the recombinant GeneVac-B vaccine, against hepatitis B, administered in the ultra-accelerated and accelerated schedules.
Person in poverty
Sponsors
Faculdade de Enfermagem Universidade Federal de Goiás
Faculdade de Enfermagem Universidade Federal de Goiás
Eligibility
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: Will be included in the study individuals aged 12 years and over; who live in poverty; who are residents of the Continental, Terra do Sol and Retiro do Bosque housing estates and who are susceptible to hepatitis B virus. Susceptibility is defined as the absence of a serological marker of acute and chronic HBV exposure and/or infection.
Exclusion criteria
Exclusion criteria: Patients with laboratory-proven human immunodeficiency virus infection or other comorbidities that contraindicate vaccination, such as immunosuppressive diseases, cancer, chronic renal failure, or continued use of corticosteroids, will be excluded from the study. Also, those who at the time of the interview present changes in elementary psychic functions that prevent them from consciously participating in the data collection process.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| After completing the three doses of the vaccination schedule, to present seroprotection against hepatitis B, considering titers of anti-HBs greater than or equal to 10 IU / L. | — |
Secondary
| Measure | Time frame |
|---|---|
| To identify which of the vaccination schedules performed presented greater adherence, considering the conclusion of the three doses in each schedule. | — |
Countries
Brazil
Contacts
Public ContactSandra Maria;Lara Cristina Souza;Guimaraes
Faculdade de Enfermagem Universidade Federal de Goiás;Faculdade de Enfermagem Universidade Federal de Goiás
Outcome results
None listed